Glucocorticoid hormones were discovered to have use as potent anti-inflammatory and
immunosuppressive therapeutics in the 1940s and their continued use and development …

Type 2 diabetes mellitus (T2DM) is a chronic, complex metabolic disease characterized by
chronic hyperglycemia causing from insufficient insulin signaling because of insulin …

Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of
hospitalization for heart failure in patients regardless of the presence or absence of …

Abstract Purpose of Review This review offers a critical narrative evaluation of emerging
evidence that sodium-glucose co-transporter-2 (SGLT2) inhibitors exert nephroprotective …

The management of type 2 diabetes mellitus (T2DM) is becoming increasingly complex.
Sodium–glucose cotransporter type 2 inhibitors (SGLT2is) are the newest antidiabetic …

Chronic kidney disease (CKD) and heart failure affect many people worldwide. Despite the
availability of pharmacological treatments, both diseases remain associated with …

Nonalcoholic fatty liver disease (NAFLD) is a spectrum of disease, extending from simple
steatosis to inflammation and fibrosis with a significant risk for the development of cirrhosis. It …

Background Sodium-glucose co-transporter-2 (SGLT2) inhibitors improve outcomes among
patients with established heart failure. Despite supportive basic science studies, there are …

Background Sodium-glucose cotransporter-2 inhibitors (SGLT2is) represent a new class of
oral hypoglycemic agents used in the treatment of type 2 diabetes mellitus. They have a …

Diabetes is the most frequent cause of chronic kidney disease (CKD), leading to nearly half
of all cases of kidney failure requiring replacement therapy. The principal cause of death …